JJR IV Acquisition Inc. and BIOX Corporation announce shareholder approval
and completion of share consolidation and continuance

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./

TORONTO, Feb. 25 /CNW/ - JJR IV Acquisition Inc. (TSXV: JJV.P) ("JJR") is pleased to announce that the shareholders of JJR approved the amalgamation (the "Amalgamation") of JJR with BIOX Corporation ("BIOX") and related matters including the consolidation of JJR's common shares on the basis of one post-consolidation common share for every 24 common shares issued and outstanding immediately before the consolidation (the "Consolidation") and the continuance of JJR under the Canada Business Corporations Act (the "Continuance"). JJR completed the Consolidation and Continuance today.

In addition, the shareholders of BIOX also approved the Amalgamation at a meeting of its shareholders held today.

The closing of the related private placement of common shares of JJR to BIOX is expected to occur on February 28, 2010 while the Amalgamation is expected to be effective on Monday March 1, 2010. Upon completion of the Amalgamation, the amalgamated corporation will be known as BIOX Corporation.

The TSX Venture Exchange had conditionally approved the qualifying transaction of JJR. In addition, the Toronto Stock Exchange (the "TSX") has conditionally approved the listing of the shares of the amalgamated corporation on the TSX. Listing of the shares is subject to BIOX fulfilling all of the requirements of the TSX on or before May 12, 2010.

Completion of the Amalgamation is subject to a number of conditions, including but not limited to, TSX Venture Exchange acceptance. There can be no assurance that the Amalgamation will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the Information Circular of JJR filed on SEDAR in connection with the Amalgamation and other matters, any information released or received with respect to the Amalgamation may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange has not in any way passed upon the merits of the Amalgamation and has not approved nor disapproved the contents of this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Notice on forward-looking statements:

This release includes forward-looking statements regarding JJR, BIOX and their respective businesses. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release, including completion of the Amalgamation and the private placement may not occur. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and JJR and BIOX undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information: Ronald D. Schmeichel, Chief Executive Officer of JJR IV Acquisition Inc. at [phone]; or Tim Haig, Chief Executive Officer of BIOX Corporation at [phone]